MedTrace Logo

Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer

NCT02628665 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-12-11

No results posted yet for this study

Summary

The therapy of photofrin PDT was effective in improving life quality of patients with advanced esophageal and/or gastric cardiac cancer and the time optimizing for employing laser irradiation was of great importance.The purpose of this study is to evaluate the clinical efficacy and adverse effects of Photodynamic Therapy (PDT) on esophageal and/or gastric cardiac cancer during different time after inject photofrin.

Conditions

  • Stage I Esophageal Adenocarcinoma
  • Stage II Esophageal Adenocarcinoma
  • Stage III Esophageal Adenocarcinoma
  • Stage I Esophageal Squamous Cell Carcinoma
  • Stage II Esophageal Squamous Cell Carcinoma
  • Stage III Esophageal Squamous Cell Carcinoma

Interventions

DRUG

photosensitizer(photofrin)

photosensitizer(photofrin): 2mg/kg

DEVICE

630 nm laser irradiation (DIOMED)

630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.

Sponsors & Collaborators

  • The First Affiliated Hospital of Henan University of Science and Technology

    lead OTHER

Principal Investigators

  • Shegan Gao, Doctor · The First Affiliated Hospital of Henan University of Science and Technology

  • Tanyou Shan, Master · The First Affiliated Hospital of Henan University of Science and Technology

  • Caihong Dong, Master · The First Affiliated Hospital of Henan University of Science and Technology

  • Xiaozhi Yuan, Master · The First Affiliated Hospital of Henan University of Science and Technology

  • Lin Guo, Bachelor · The First Affiliated Hospital of Henan University of Science and Technology

  • Lijuan Zhang, Bachelor · The First Affiliated Hospital of Henan University of Science and Technology

  • Gailin Wang, Bachelor · The First Affiliated Hospital of Henan University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-10-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02628665 on ClinicalTrials.gov